List of Excipients in Branded Drug ROXICODONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	ROXICODONE	oxycodone hydrochloride	16590-913	CELLULOSE, MICROCRYSTALLINE
STAT RX USA LLC	ROXICODONE	oxycodone hydrochloride	16590-913	FD&C BLUE NO. 2
STAT RX USA LLC	ROXICODONE	oxycodone hydrochloride	16590-913	LACTOSE MONOHYDRATE
STAT RX USA LLC	ROXICODONE	oxycodone hydrochloride	16590-913	SODIUM STARCH GLYCOLATE TYPE A POTATO
STAT RX USA LLC	ROXICODONE	oxycodone hydrochloride	16590-913	STARCH, CORN
STAT RX USA LLC	ROXICODONE	oxycodone hydrochloride	16590-913	STEARIC ACID

Roxicodone Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

Roxicodone is an immediate-release oxycodone hydrochloride tablet. Its commercial opportunity is primarily generic supply, formulation optimization, and differentiated delivery rather than protection of the legacy brand. The product is a Schedule II opioid, faces intensive FDA scrutiny, and has limited room for excipient-driven differentiation because any reformulation must preserve oxycodone exposure, tablet performance, dose uniformity, stability, and abuse-risk controls.

The strongest opportunities are low-cost, low-variability immediate-release tablets; excipient systems that improve manufacturability and patient tolerability; and, where commercially justified, new 505(b)(2) products with modified pharmacokinetics or abuse-deterrent properties. A conventional Roxicodone-equivalent product has weak patent protection and substantial regulatory, controlled-substance, liability, and channel-access barriers.

What is Roxicodone and how is it regulated?

Roxicodone is an immediate-release oral tablet containing oxycodone hydrochloride. The reference product is indicated for the management of pain severe enough to require an opioid analgesic when alternative treatments are inadequate. It is available in multiple strengths, including 5 mg, 15 mg, and 30 mg tablets, according to FDA labeling.[1]

Attribute	Roxicodone
Active ingredient	Oxycodone hydrochloride
Dosage form	Immediate-release tablet
Regulatory pathway	NDA reference product; generic versions generally use ANDA pathway
Controlled-substance classification	Schedule II
Primary therapeutic area	Severe acute and chronic pain
Release profile	Immediate release
Main commercial substitutes	Generic oxycodone IR, hydrocodone combinations, morphine IR, tramadol in selected settings
Key formulation constraints	Dose uniformity, dissolution, stability, abuse risk, tablet integrity
Principal regulatory agency	U.S. Food and Drug Administration

FDA labeling warns about respiratory depression, misuse, addiction, abuse, overdose, and death. The drug is subject to opioid-specific prescribing, dispensing, manufacturing, distribution, recordkeeping, and diversion controls.[1,2]

What excipients are used in Roxicodone tablets?

The Roxicodone labeling identifies conventional tablet excipients, including lactose, microcrystalline cellulose, magnesium stearate, starch-related processing agents, povidone, sodium starch glycolate, colloidal silicon dioxide, and permitted colorants depending on tablet strength and presentation.[1]

The exact excipient composition matters for three reasons:

1. It affects tablet compression, friability, disintegration, and dissolution.
2. It can create patient-selection issues involving lactose intolerance, colorants, or excipient sensitivities.
3. It can distinguish a generic product operationally without creating meaningful exclusivity.

A proposed product should use the currently applicable FDA-approved label and product-specific inactive-ingredient data as the controlling source for formulation decisions. Excipient composition can change across approved manufacturers and strengths.

What excipient strategy is appropriate for Roxicodone?

The optimal strategy is a conservative immediate-release tablet platform with tight control over powder flow, content uniformity, mechanical strength, disintegration, and dissolution. Excipient innovation should support manufacturing reliability rather than materially change release behavior.

Core excipient objectives

Objective	Relevant excipient functions	Commercial value
Content uniformity	Diluent selection, ordered mixing, low-segregation powder system	Reduces batch failures and supports scale-up
Tablet strength	Microcrystalline cellulose, appropriate binder, compression optimization	Improves handling and packaging performance
Rapid disintegration	Superdisintegrant and porosity control	Supports immediate-release dissolution
Lubrication	Magnesium stearate or alternative lubricant at controlled concentration	Prevents sticking while limiting dissolution impact
Flow	Colloidal silicon dioxide or comparable glidant	Improves tablet-weight control
Moisture stability	Low-moisture excipient grades and protective packaging	Reduces degradation and physical instability
Patient acceptability	Colorant, tablet size, swallowability, and low odor	Supports adherence and product differentiation
Manufacturing flexibility	Direct compression or robust granulation platform	Lowers cost and improves supply resilience

Direct compression versus wet granulation

Direct compression can reduce processing steps, water exposure, equipment requirements, and manufacturing cost. It is attractive for a high-volume generic oxycodone product if the active pharmaceutical ingredient has acceptable flow and compactibility after blending.

Wet granulation can improve blend uniformity and tablet strength but adds process complexity, drying requirements, residual-moisture control, and scale-up risk. It may be justified when the selected oxycodone hydrochloride grade has poor flow, segregation risk, or inadequate compactibility.

For a commercial generic, the decision should be based on process capability rather than novelty. A simpler formulation with reliable dissolution and low batch variability is generally more valuable than a complex excipient system that creates a distinctive but non-protectable product.

What formulation patents protect Roxicodone?

No meaningful active patent barrier is generally associated with the conventional Roxicodone immediate-release tablet as a legacy product. Oxycodone hydrochloride and conventional immediate-release tablet technology are mature. Generic oxycodone IR products have historically entered through ANDA pathways after the relevant reference-product exclusivity and patent barriers expired.

The principal intellectual-property opportunities are not likely to arise from the basic Roxicodone formula. They would arise from:

• Abuse-deterrent matrices or coating systems.
• Multiparticulate or orally disintegrating delivery systems.
• Novel taste-masking systems.
• Extended-release or biphasic release profiles.
• Fixed-dose combinations.
• New indications supported by clinical data.
• Manufacturing processes with measurable product-performance advantages.
• Packaging and dispensing systems that reduce diversion or dosing error.

A patent on a routine excipient substitution is unlikely to provide strong commercial protection unless it produces an unexpected technical result, solves a documented manufacturing problem, or is linked to a clinically relevant product characteristic.

How many patents cover Roxicodone?

The legacy immediate-release Roxicodone product does not present the type of active patent estate associated with recently launched branded medicines. A current Orange Book review should be performed against the relevant reference listed drug and dosage form before filing or acquisition decisions.[3]

The practical patent position is:

IP category	Roxicodone commercial relevance
Oxycodone compound patents	Expired or commercially obsolete for conventional generic entry
Conventional immediate-release tablet patents	Limited value and generally vulnerable to design-around
Formulation patents	Relevant only if a novel delivery or abuse-deterrent system is developed
Method-of-use patents	Potentially relevant for a new indication, not routine pain treatment
Manufacturing patents	Possible source of process protection, but difficult to enforce if product equivalence is not exposed
Packaging patents	Narrow commercial value unless tied to a controlled-distribution system
Trade secrets	Important for process controls, supplier qualification, and yield

The commercial defense for a standard generic is more likely to depend on cost, supply reliability, quality history, contract access, and DEA-compliant distribution than on patent exclusivity.

When does Roxicodone lose exclusivity?

Roxicodone has already lost meaningful market exclusivity for conventional immediate-release oxycodone tablets. Generic oxycodone IR products are commercially established, and the product is not protected by the type of current brand exclusivity that would block routine ANDA competition.

FDA approval status, therapeutic-equivalence ratings, and current marketing status must be checked in the Orange Book and Drugs@FDA before a transaction or launch decision.[3,4] Product-level issues can include discontinued reference presentations, withdrawn strengths, supply interruptions, and manufacturer-specific marketing status.

A new product using the Roxicodone active ingredient could obtain limited regulatory exclusivity only through a qualifying innovation, such as:

• A new chemical entity, which oxycodone is not.
• A new indication supported by the applicable statutory requirements.
• A new dosage form or formulation approved through a 505(b)(2) application.
• Orphan-drug exclusivity, if the product qualified for an orphan indication.
• Pediatric exclusivity, if granted based on a qualifying FDA request.

These mechanisms would protect the new product or indication, not restore broad exclusivity to conventional oxycodone IR tablets.

What FDA pathway applies to a Roxicodone generic?

A conventional generic oxycodone immediate-release tablet would generally use an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug and meet FDA requirements for chemistry, manufacturing, controls, labeling, facilities, and quality systems.[5]

A materially different formulation may require a 505(b)(2) NDA. That pathway becomes more relevant if the proposed product changes:

• Release rate.
• Route of administration.
• Dosage form.
• Excipient system in a way that affects clinical performance.
• Abuse-deterrent properties.
• Patient population or indication.
• Dosing frequency.

Excipient changes that do not alter active-ingredient exposure may remain within an ANDA, but the applicant must still establish equivalence and address inactive-ingredient safety. A change that affects dissolution or pharmacokinetics can create additional bioequivalence and clinical risks.

What are the commercial opportunities for Roxicodone excipient innovation?

1. Cost-optimized generic tablets

This is the largest practical opportunity. A manufacturer can compete through:

• Direct-compression processing.
• Reduced excipient count.
• Dual-purpose excipients.
• Higher-yield compression.
• Lower tablet rejection rates.
• Common platform excipients across 5 mg, 15 mg, and 30 mg strengths.
• Supplier redundancy for critical materials.

The value comes from manufacturing economics and reliable supply rather than patent exclusivity.

2. Excipient systems that improve dissolution robustness

Oxycodone IR tablets must meet immediate-release dissolution expectations across relevant production lots. A robust disintegrant and lubricant system can reduce sensitivity to compression force, lubricant mixing time, excipient grade, and storage conditions.

This may be commercially valuable where competitors experience dissolution drift or production variability. The advantage is usually protected as know-how and process capability, not as a broad formulation patent.

3. Lactose-free or reduced-allergen positioning

A lactose-free product could address patients and institutions seeking to avoid lactose. The opportunity is limited because lactose intolerance does not generally prevent use of every lactose-containing tablet, and many alternative generic formulations may already exist.

A lactose-free platform can still support procurement differentiation if it preserves:

• Rapid disintegration.
• Low tablet weight.
• Acceptable mouthfeel and swallowability.
• Stable color and appearance.
• Comparable bioavailability.

The label must accurately identify inactive ingredients and avoid unsupported allergy claims.

4. Colorant and excipient simplification

Colorant-free or simplified-color presentations may appeal to institutional buyers and patients with sensitivity concerns. The tradeoff is that strength differentiation becomes more dependent on tablet shape, imprinting, embossing, packaging, and bar-code controls.

Because oxycodone tablets are vulnerable to diversion and medication errors, strength identification must remain clear. A colorant change may also require careful review of product appearance, labeling, stability, and bioequivalence implications.

5. Abuse-deterrent formulations

Abuse-deterrent oxycodone is the most technically differentiated opportunity, but it is not a routine excipient substitution. The FDA evaluates abuse-deterrent products against specific abuse routes and does not consider abuse-deterrent labeling equivalent to abuse-proof performance.[6]

Potential technologies include:

• Hard-to-crush matrices.
• Gelling agents that limit syringeability.
• Sequestered or chemically immobilized opioid.
• Irritant systems.
• Combination designs that reduce tampering.
• Physical barriers to extraction.

These systems may support a 505(b)(2) strategy and patent filings, but development costs, human abuse-potential studies, in vitro manipulation testing, clinical requirements, manufacturing complexity, and payer acceptance create substantial risk.

6. Hospital and institutional packaging

Unit-dose packaging, tamper-evident configurations, serialized inventory controls, and dispensing-system compatibility can create commercial value without changing the tablet. These measures can reduce medication errors and improve inventory control.

Packaging does not eliminate diversion risk. It can, however, support hospital contracting and controlled-substance accountability when integrated with compliant distribution and pharmacy systems.

What generic entry risks exist for Roxicodone?

The largest risks are regulatory and commercial rather than patent-based.

Risk	Effect on launch
DEA quota and controlled-substance allocation	Can restrict production and inventory
Opioid manufacturing and distribution scrutiny	Raises compliance cost and audit exposure
Bioequivalence failure	Delays approval and increases development cost
Dissolution variability	Creates batch-release and post-approval risk
Supplier concentration	Increases interruption risk for API or excipients
Opioid litigation and public-policy exposure	Raises legal and insurance costs
Wholesaler and pharmacy restrictions	Limits market access
Price compression	Reduces return on standard generic tablets
Diversion concerns	Can affect contracting and distribution
Competition from multiple ANDA holders	Reduces sustainable margin

Manufacturers also face FDA postmarket surveillance, current good manufacturing practice requirements, adverse-event reporting, recall exposure, and controlled-substance recordkeeping obligations.[2,5]

Which companies are challenging or competing with Roxicodone?

Competition comes primarily from generic manufacturers of oxycodone hydrochloride immediate-release tablets and from alternative opioid products. The relevant competitive set includes:

• Generic oxycodone IR suppliers.
• Branded or authorized-generic distributors.
• Manufacturers of hydrocodone-acetaminophen and other opioid analgesics.
• Morphine IR suppliers.
• Non-opioid analgesic manufacturers.
• Developers of abuse-deterrent opioid formulations.

The competitive landscape changes frequently because manufacturers enter, exit, discontinue presentations, or experience quota and supply constraints. FDA’s Orange Book, Drugs@FDA, and drug-shortage databases are the controlling sources for current supplier status.[3,4,7]

What is the Orange Book status of Roxicodone?

The Orange Book should be used to confirm the current reference listed drug, active applicants, therapeutic-equivalence ratings, dosage strengths, and any listed patents or exclusivity. For a mature immediate-release oxycodone product, the expected commercial profile is multiple generic equivalents and limited remaining listed-patent leverage.[3]

An applicant should separately verify:

1. The exact reference listed drug.
2. The strength and dosage form.
3. Whether the reference product is currently marketed.
4. Whether the proposed formulation is pharmaceutically equivalent.
5. Whether any Paragraph IV certification is required.
6. Whether FDA has listed product-specific exclusivity or patent information.

Are Paragraph IV challenges relevant to Roxicodone?

Paragraph IV litigation is unlikely to be the main issue for a conventional Roxicodone-equivalent tablet because the core product is mature and genericized. It becomes relevant if a new oxycodone formulation has unexpired listed patents, especially an abuse-deterrent or modified-release product.

A Paragraph IV strategy may be commercially rational when:

• The reference product has high revenue.
• The listed patents are vulnerable to invalidity or non-infringement arguments.
• The challenger can launch at risk or secure a settlement.
• The formulation has enough margin to support litigation.
• The applicant has manufacturing capacity and controlled-substance distribution access.

For standard Roxicodone IR, the return from patent litigation is generally less attractive than the return from efficient manufacturing and reliable supply.

What licensing deals could support a Roxicodone opportunity?

Licensing opportunities are most plausible in technology, not in the legacy Roxicodone brand. Potential targets include:

• Abuse-deterrent excipient or matrix technology.
• Taste-masking and orally disintegrating tablet platforms.
• Controlled-substance packaging and authentication systems.
• High-throughput direct-compression processes.
• Specialty API supply agreements.
• Contract manufacturing capacity with DEA authorization.
• Hospital or specialty-pharmacy distribution arrangements.

A license should be evaluated on freedom to operate, territorial rights, controlled-substance manufacturing permissions, clinical and CMC data transfer, patent term, and whether the technology creates a clinically or commercially visible advantage.

How strong is the patent estate for Roxicodone?

The patent estate for conventional immediate-release Roxicodone is weak as a barrier to generic entry. The stronger assets are operational:

• Validated manufacturing processes.
• Supplier qualification.
• Low-variability excipient grades.
• Stable API sourcing.
• DEA quota access.
• Quality and inspection history.
• Institutional contracting.
• Distribution controls.
• Product-specific know-how.

A new abuse-deterrent or modified-release oxycodone product could support a stronger patent estate, but its value would depend on enforceability, clinical differentiation, FDA labeling, payer coverage, and physician adoption.

How does Roxicodone compare with extended-release oxycodone?

Roxicodone is immediate release, while extended-release oxycodone products use delivery systems designed to maintain exposure over a longer period. The formulation and regulatory strategies differ materially.

Issue	Roxicodone IR	Extended-release oxycodone
Dosing objective	Rapid analgesic onset	Prolonged exposure
Excipient priority	Disintegration and rapid dissolution	Release control and abuse resistance
Generic pathway	Conventional ANDA possible	Product-specific bioequivalence and formulation challenges
Patent opportunity	Limited for basic tablet	Greater opportunity from release-control systems
Abuse-deterrence relevance	Possible but difficult	Historically central to some products
Manufacturing burden	Relatively lower	Higher process and performance complexity
Commercial differentiation	Cost, supply, packaging	Duration, formulation, labeling, abuse-deterrence profile

What revenue exposure exists for a Roxicodone launch?

Revenue exposure depends on tablet volume, strength mix, average selling price, customer concentration, controlled-substance allocation, and generic price erosion. Public filings do not provide a uniform, current revenue figure for all Roxicodone-equivalent products because sales are often reported within broader generic or opioid portfolios.

A financial model should use scenario ranges based on:

• Annual prescriptions or institutional doses.
• Net price per tablet by strength.
• Expected price erosion after additional ANDA entrants.
• API and excipient cost.
• DEA quota utilization.
• Recall and compliance reserves.
• Wholesaler deductions and chargebacks.
• Required inventory and security spending.

The commercial upside of a conventional generic is usually volume-driven and margin-sensitive. The upside of a differentiated formulation is potentially larger per unit but requires substantially greater development and regulatory investment.

Key Takeaways

• Roxicodone is an immediate-release oxycodone hydrochloride tablet with a mature generic market.
• Conventional excipient innovation should prioritize content uniformity, dissolution robustness, tablet strength, stability, and low manufacturing cost.
• The legacy product has limited patent-based exclusivity and little value from routine excipient substitution patents.
• A standard generic generally fits the ANDA pathway; materially modified products may require a 505(b)(2) NDA.
• Abuse-deterrent oxycodone is the clearest high-differentiation opportunity but carries significant technical, clinical, regulatory, and commercial risk.
• Lactose-free, colorant-simplified, hospital-ready, and packaging-enhanced products may support procurement differentiation without creating broad exclusivity.
• The principal barriers are controlled-substance compliance, DEA quota, opioid liability, supply reliability, bioequivalence, and price erosion.
• For a conventional Roxicodone-equivalent product, manufacturing excellence and distribution access are more valuable than a narrow formulation patent.

FAQs

Can a lactose-free Roxicodone generic obtain market exclusivity?

No. A lactose-free formulation may differentiate a product commercially, but the excipient change alone generally does not create regulatory exclusivity. It must still satisfy applicable ANDA requirements and inactive-ingredient safety standards.

Can an excipient change trigger new clinical trials for oxycodone IR?

It can if the change affects drug release, absorption, bioavailability, tolerability, or product performance. Routine changes that preserve pharmaceutical equivalence may be handled within an ANDA, but FDA determines the required evidence based on the formulation and risk.

Is an abuse-deterrent Roxicodone product automatically protected from generic competition?

No. Abuse-deterrent properties may support patents, regulatory differentiation, or labeling claims, but they do not automatically prevent approval of a conventional generic unless applicable patents, exclusivity, and FDA requirements block that product.

What excipient is most important for immediate-release oxycodone tablets?

No single excipient controls the product. The commercial priority is the integrated system of diluent, binder, disintegrant, lubricant, glidant, moisture-control strategy, and compression process.

Can a manufacturer use the Roxicodone name for a generic oxycodone product?

Generally no. The Roxicodone trademark and brand identity are distinct from the active ingredient. A generic applicant must use FDA-approved proprietary or established nonproprietary labeling and cannot imply brand affiliation without authorization.

References

1. U.S. Food and Drug Administration. (2024). Roxicodone (oxycodone hydrochloride) tablets: Prescribing information.
2. U.S. Drug Enforcement Administration. (2024). Controlled substances act, Schedule II substances.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
5. U.S. Food and Drug Administration. (2024). Generic drug facts and ANDA requirements.
6. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling.
7. U.S. Food and Drug Administration. (2024). Drug shortages database.